- Home
- YMAB
as 12-18-2024 10:02am EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 482.4M | IPO Year: | 2018 |
| Target Price: | $21.00 | AVG Volume (30 days): | 243.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.09 - $20.90 | Next Earning Date: | 11-08-2024 |
| Revenue: | $84,553,000 | Revenue Growth: | -8.99% |
| Revenue Growth (this year): | 6.46% | Revenue Growth (next year): | 20.68% |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
11 days ago
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
MT Newswires
13 days ago
Brookline Capital Initiates Y-mAbs Therapeutics at Buy With $17 Price Target
GlobeNewswire
21 days ago
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
MT Newswires
a month ago
Oppenheimer Initiates Coverage on Y-mAbs Therapeutics With Outperform Rating, $23 Price Target
Simply Wall St.
a month ago
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth
GuruFocus.com
a month ago
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
Zacks
a month ago
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.